Vertex Pharmaceuticals Stock: Q1 2026 Revenue Hits $2.99B With Full-Year Guidance Intact
Vertex Pharmaceuticals (VRTX) reported Q1 2026 total product revenue of $2.99 billion, an 8% increase year-over-year, and non-GAAP EPS of $4.47. The company reiterated its full-year 2026 revenue guidance of $12.95 billion to $13.1 billion, driven by growth in CF products and new disease areas like CASGEVY and JOURNAVX. TIKR’s valuation model suggests an 89% upside for the stock, pricing it at $803, contingent on the successful scaling of its non-CF portfolio and continued execution of its product launches.
https://www.tikr.com/blog/vertex-pharmaceuticals-stock-q1-2026-revenue-hits-2-99b-with-full-year-guidance-intact